Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection.

@article{Kloner2008GlucoseinsulinpotassiumFA,
  title={Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection.},
  author={Robert A. Kloner and Richard W. Nesto},
  journal={Circulation},
  year={2008},
  volume={117 19},
  pages={2523-33}
}
The “holy grail” in the field of cardioprotection is to develop pharmacological agents that can be administered as adjunctive treatment to reperfusion that will reduce myocardial infarct size and improve clinical outcomes. Numerous pharmacological agents and strategies have been studied over the years with variable results in both animal models and humans. Of drugs that have been studied, only a few have shown benefit in clinical trials. Aside from agents or devices than can restore and… CONTINUE READING